- Home
- ORIS vs IKT Comparison
ORIS vs IKT Comparison
Compare ORIS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIS
- IKT
- Stock Information
- Founded
- ORIS 2014
- IKT 2008
- Country
- ORIS China
- IKT United States
- Employees
- ORIS N/A
- IKT N/A
- Industry
- ORIS Farming/Seeds/Milling
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ORIS Consumer Staples
- IKT Health Care
- Exchange
- ORIS Nasdaq
- IKT Nasdaq
- Market Cap
- ORIS 182.0M
- IKT 159.2M
- IPO Year
- ORIS 2024
- IKT 2020
- Fundamental
- Price
- ORIS $6.41
- IKT $2.01
- Analyst Decision
- ORIS
- IKT Strong Buy
- Analyst Count
- ORIS 0
- IKT 2
- Target Price
- ORIS N/A
- IKT $6.50
- AVG Volume (30 Days)
- ORIS 212.0K
- IKT 336.1K
- Earning Date
- ORIS 12-03-2024
- IKT 11-14-2024
- Dividend Yield
- ORIS N/A
- IKT N/A
- EPS Growth
- ORIS N/A
- IKT N/A
- EPS
- ORIS 0.96
- IKT N/A
- Revenue
- ORIS $24,122,000.00
- IKT $1.00
- Revenue This Year
- ORIS N/A
- IKT N/A
- Revenue Next Year
- ORIS N/A
- IKT N/A
- P/E Ratio
- ORIS $7.02
- IKT N/A
- Revenue Growth
- ORIS N/A
- IKT N/A
- 52 Week Low
- ORIS $4.80
- IKT $0.85
- 52 Week High
- ORIS $11.75
- IKT $3.82
- Technical
- Relative Strength Index (RSI)
- ORIS N/A
- IKT 42.03
- Support Level
- ORIS N/A
- IKT $1.94
- Resistance Level
- ORIS N/A
- IKT $2.10
- Average True Range (ATR)
- ORIS 0.00
- IKT 0.32
- MACD
- ORIS 0.00
- IKT -0.13
- Stochastic Oscillator
- ORIS 0.00
- IKT 13.40
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is a company who is an integrated supplier of tea products in Mainland China. Their major tea products include primarily-processed tea consisting of white tea and black tea, and refined white tea and black tea. Its business operations are vertically integrated, covering cultivation, processing of tea leaves and the sale of tea products to tea business operators (such as wholesale distributors) and end-user retail customers in Mainland China.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.